Balloon-occluded hepatic arterial infusion for unresectable hepatocellular carcinoma: a phase II trial interim analysis - Takeaways - MDSpire

Balloon-occluded hepatic arterial infusion for unresectable hepatocellular carcinoma: a phase II trial interim analysis

  • By

  • Feng Li

  • Jian Zhang

  • Xiangbo An

  • Jianfei Liu

  • Benkei Li

  • Haiwei Li

  • Li Jun

  • Ningfang Wang

  • Guinan Jiang

  • Ye Jiang

  • Dehui Zhang

  • Fei Gao

  • Lei Song

  • Jun Zhou

  • Wenheng Zheng

  • Min Ji

  • Feng Wang

  • June 1, 2026

  • 0 min

Share

  • 1

    The phase II study evaluated the efficacy and safety of balloon-occluded hepatic arterial infusion chemotherapy (bHAIC) in unresectable hepatocellular carcinoma (HCC).

  • 2

    A total of 50 patients underwent successful bHAIC procedures, with an objective response rate (ORR) of 53.3% per RECIST 1.1 and 82.2% per modified RECIST criteria.

  • 3

    Among treatment-naive patients, the ORR reached 88.9% according to modified RECIST, with 15 patients achieving radiological complete response.

  • 4

    Seventy-seven percent of patients with elevated alpha-fetoprotein (AFP) levels experienced a reduction of over 50% in their AFP levels post-treatment.

  • 5

    All adverse events related to bHAIC were manageable through medication or dose adjustments, indicating an acceptable safety profile.

Original Source(s)

Balloon-occluded hepatic arterial infusion for unresectable hepatocellular carcinoma: a phase II trial interim analysis

  • by Feng Li, Jian Zhang, Xiangbo An, Jianfei Liu, Benkei Li, Haiwei Li, Li Jun, Ningfang Wang, Guinan Jiang, Ye Jiang, Dehui Zhang, Fei Gao, Lei Song, Jun Zhou, Wenheng Zheng, Min Ji, Feng Wang

  • June 1, 2026

Related Content

Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients

Exercise interventions for depressive symptoms in adults with lung and digestive cancer: a meta-analysis of randomized controlled trials

Treatment of parotid gland oncocytoma: a case report from a radiation oncologist’s perspective